Skip to main navigation Skip to search Skip to main content

CASCADE protocol: exploring current viral and host characteristics, measuring clinical and patient-reported outcomes, and understanding the lived experiences and needs of individuals with recently acquired HIV infection through a multicentre mixed-methods observational study in Europe and Canada

  • For CASCADE Collaboration
  • University College London
  • Central and North West London NHS Foundation Trust
  • National and Kapodistrian University of Athens
  • Southern Alberta HIV Clinic
  • University of Modena and Reggio Emilia
  • Université Paris-Sud
  • Île-de-France
  • Karolinska Institutet
  • Sorbonne Université
  • Centro Nacional de Epidemiología
  • Centro de Investigación Biomédica en Red
  • HIV Monitoring Foundation, Amsterdam, Netherlands
  • Bordeaux Population Health  Centre de Recherche U1219
  • Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, ISSPAM, Marseilles, France

Research output: Contribution to journalArticleAcademicpeer-review

23 Downloads (Pure)

Abstract

INTRODUCTION: Despite the availability of pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART), 21 793 people were newly diagnosed with HIV in Europe in 2019. The Concerted action on seroconversion to AIDS and death in Europe study aims to understand current drivers of the HIV epidemic; factors associated with access to, and uptake of prevention methods and ART initiation; and the experiences, needs and outcomes of people with recently acquired HIV. METHODS AND ANALYSIS: This longitudinal observational study is recruiting participants aged ≥16 years with documented laboratory evidence of HIV seroconversion from clinics in Canada and six European countries. We will analyse data from medical records, self-administered questionnaires, semistructured interviews and participatory photography. We will assess temporal trends in transmitted drug resistance and viral subtype and examine outcomes following early ART initiation. We will investigate patient-reported outcomes, well-being, and experiences of, knowledge of, and attitudes to HIV preventions, including PrEP. We will analyse qualitative data thematically and triangulate quantitative and qualitative findings. As patient public involvement is central to this work, we have convened a community advisory board (CAB) comprising people living with HIV. ETHICS AND DISSEMINATION: All respective research ethics committees have approval for data to contribute to international collaborations. Written informed consent is required to take part. A dissemination strategy will be developed in collaboration with CAB and the scientific committee. It will include peer-reviewed publications, conference presentations and accessible summaries of findings on the study's website, social media and via community organisations.
Original languageEnglish
Article numbere070837
Pages (from-to)e070837
JournalBMJ open
Volume13
Issue number5
DOIs
Publication statusPublished - 11 May 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being
  2. SDG 5 - Gender Equality
    SDG 5 Gender Equality
  3. SDG 16 - Peace, Justice and Strong Institutions
    SDG 16 Peace, Justice and Strong Institutions

Keywords

  • EPIDEMIOLOGIC STUDIES
  • HIV & AIDS
  • INFECTIOUS DISEASES
  • Primary Prevention

Fingerprint

Dive into the research topics of 'CASCADE protocol: exploring current viral and host characteristics, measuring clinical and patient-reported outcomes, and understanding the lived experiences and needs of individuals with recently acquired HIV infection through a multicentre mixed-methods observational study in Europe and Canada'. Together they form a unique fingerprint.

Cite this